Affini-T Therapeutics

Affini T Therapeutics

Biotechnology, 343 Arsenal St, Watertown, Massachusetts, 02472, United States, 51-200 Employees

affinittx.com

  • facebook
  • LinkedIn

Who is AFFINI-T THERAPEUTICS

Affini-T is a leading precision immunotherapy company targeting core oncogenic driver mutations to develop potentially curative therapies for patients with solid tumors. Our differentiate...

Read More

map
  • 343 Arsenal St, Watertown, Massachusetts, 02472, United States Headquarters: 343 Arsenal St, Watertown, Massachusetts, 02472, United States
  • 2021 Date Founded: 2021
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $10 Million to $25 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from AFFINI-T THERAPEUTICS

Affini-T Therapeutics Org Chart and Mapping

Employees

Scott Smith

Tech Transfer Engineer III

Joseph Lee

Senior Director, Product Sciences

Hui-Wen Liu

Principal Scientist, Assay Development

Damien Hallet

Vice President - Head of Cmc

Donovan Farris

Director of Manufacturing

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Affini-T Therapeutics

Answer: Affini-T Therapeutics's headquarters are located at 343 Arsenal St, Watertown, Massachusetts, 02472, United States

Answer: Affini-T Therapeutics's official website is https://affinittx.com

Answer: Affini-T Therapeutics's revenue is $10 Million to $25 Million

Answer: Affini-T Therapeutics's SIC: 2836

Answer: Affini-T Therapeutics's NAICS: 541714

Answer: Affini-T Therapeutics has 51-200 employees

Answer: Affini-T Therapeutics is in Biotechnology

Answer: Affini-T Therapeutics contact info: Phone number: Website: https://affinittx.com

Answer: Affini-T is a leading precision immunotherapy company targeting core oncogenic driver mutations to develop potentially curative therapies for patients with solid tumors. Our differentiated cell therapy platforms harness state-of-the-art engineering, synthetic biology, and gene editing capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access